A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

NCT01468467 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: AC220

Sponsor

Daiichi Sankyo

Collaborators

[object Object]